TELA Bio financials
$1.24+0.81%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 |
|---|---|---|---|---|---|---|---|
| Revenue | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M | $18.2M | $15.4M |
| Gross profit | $54.3M | $46.5M | $40.1M | $27.0M | $18.8M | $11.2M | $9.3M |
| Gross margin | 67.7% | 67.1% | 68.6% | 65.3% | 63.9% | 61.7% | 60.0% |
| Operating income | -$33.8M | -$41.7M | -$44.1M | -$39.0M | -$29.5M | -$25.3M | -$19.2M |
| Net income | -$38.8M | -$37.8M | -$46.7M | -$44.3M | -$33.3M | -$28.8M | -$30.2M |
| Net margin | −48.4% | −54.6% | −79.8% | −106.9% | −112.9% | −158.1% | −195.6% |
| Diluted EPS | $-0.83 | $-1.33 | $-2.04 | $-2.72 | $-2.30 | $-2.23 | $-17.10 |
| EBITDA | -$32.7M | -$40.7M | -$43.3M | -$37.8M | -$28.9M | -$24.8M | -$18.6M |
| Operating cash flow | -$28.2M | -$41.6M | -$40.9M | -$40.7M | -$30.4M | -$24.5M | -$25.5M |
| Free cash flow | -$28.7M | -$42.6M | -$41.5M | -$41.6M | -$31.1M | -$24.6M | -$25.7M |
| Diluted shares | 46.9M | 28.5M | 22.9M | 16.3M | 14.5M | 12.9M | 1.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $50.8M | $52.7M | $46.7M | $42.0M | $43.9M | $74.4M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $55.7M | $41.1M | $40.5M | $39.9M | $0.00 | $30.8M |
| Total assets | $81.4M | $86.6M | $78.0M | $67.9M | $62.5M | $86.5M |
| Total liabilities | $75.1M | $58.1M | $59.2M | $53.5M | $42.4M | $37.4M |
| Shareholders' equity | $6.3M | $28.5M | $18.9M | $14.3M | $20.1M | $49.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology